BR112022015502A2 - Tratamento da infecção por coronavírus com interferon lambda - Google Patents

Tratamento da infecção por coronavírus com interferon lambda

Info

Publication number
BR112022015502A2
BR112022015502A2 BR112022015502A BR112022015502A BR112022015502A2 BR 112022015502 A2 BR112022015502 A2 BR 112022015502A2 BR 112022015502 A BR112022015502 A BR 112022015502A BR 112022015502 A BR112022015502 A BR 112022015502A BR 112022015502 A2 BR112022015502 A2 BR 112022015502A2
Authority
BR
Brazil
Prior art keywords
treatment
interferon lambda
virus infection
corona virus
lambda
Prior art date
Application number
BR112022015502A
Other languages
English (en)
Inventor
Glenn Jeffrey
Choong Ingrid
Hislop Colin
Original Assignee
Eiger Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Biopharmaceuticals Inc filed Critical Eiger Biopharmaceuticals Inc
Publication of BR112022015502A2 publication Critical patent/BR112022015502A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

TRATAMENTO DA INFECÇÃO POR CORONAVÍRUS COM INTERFERON LAMBDA. São fornecidos métodos de tratamento de uma infecção por coronavírus em um indivíduo humano. Em algumas modalidades, o método compreende a administração subcutânea ao indivíduo de uma quantidade terapeuticamente eficaz de interferon peguilado lambda-1a.
BR112022015502A 2020-02-06 2021-02-05 Tratamento da infecção por coronavírus com interferon lambda BR112022015502A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062971194P 2020-02-06 2020-02-06
US202063017614P 2020-04-29 2020-04-29
US202063021552P 2020-05-07 2020-05-07
US202063091881P 2020-10-14 2020-10-14
US202063093334P 2020-10-19 2020-10-19
PCT/US2021/016963 WO2021159027A1 (en) 2020-02-06 2021-02-05 Treatment of coronavirus infection with interferon lambda

Publications (1)

Publication Number Publication Date
BR112022015502A2 true BR112022015502A2 (pt) 2022-09-27

Family

ID=77199418

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015502A BR112022015502A2 (pt) 2020-02-06 2021-02-05 Tratamento da infecção por coronavírus com interferon lambda

Country Status (12)

Country Link
US (1) US20230285510A1 (pt)
EP (1) EP4100047A4 (pt)
JP (1) JP2023513209A (pt)
KR (1) KR20220139922A (pt)
CN (1) CN115209914A (pt)
AU (1) AU2021217681A1 (pt)
BR (1) BR112022015502A2 (pt)
CA (1) CA3169594A1 (pt)
CL (1) CL2022002104A1 (pt)
IL (1) IL295040A (pt)
MX (1) MX2022009712A (pt)
WO (1) WO2021159027A1 (pt)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110392A2 (en) * 2003-04-01 2004-12-23 Intermune, Inc. Compositions and methods for treating coronavirus infection and sars
CA2534907C (en) * 2003-08-07 2014-04-29 Zymogenetics, Inc. Homogeneous preparations of il-28 and il-29
WO2006076014A2 (en) * 2004-04-30 2006-07-20 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Interferon-alpha constructs for use in the treatment of sars

Also Published As

Publication number Publication date
CA3169594A1 (en) 2021-08-12
EP4100047A4 (en) 2024-03-13
KR20220139922A (ko) 2022-10-17
WO2021159027A1 (en) 2021-08-12
CL2022002104A1 (es) 2023-03-24
AU2021217681A1 (en) 2022-08-18
MX2022009712A (es) 2022-09-09
US20230285510A1 (en) 2023-09-14
EP4100047A1 (en) 2022-12-14
CN115209914A (zh) 2022-10-18
IL295040A (en) 2022-09-01
WO2021159027A9 (en) 2022-09-22
JP2023513209A (ja) 2023-03-30

Similar Documents

Publication Publication Date Title
ATE373679T1 (de) Antimikrobiell wirksames oder endotoxin neutralisierendes polypeptid
RO115700B1 (ro) Metodă de tratament cu interferon
WO2006110655A3 (en) Compounds, compositions and methods for the treatment of poxvirus infections
ATE497775T1 (de) Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
MX2021002147A (es) Tratamiento de la infección por virus de la hepatitis delta con interferón lambda.
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
EA201691347A2 (ru) Терапия глатирамером ацетатом с низкой кратностью
CY1124220T1 (el) Θεραπεια της λοιμωξης του ιου της ηπατιτιδας δελτα με ιντερφερονη λαμδα
BR9607601A (pt) Uso de ácido hialurÈnico para o tratamento de cistite intersticial
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
BR112021013415A2 (pt) Proteínas de fusão multifuncionais e usos das mesmas
FR2910327B1 (fr) Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
BR112022022599A2 (pt) Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma
BR112022015502A2 (pt) Tratamento da infecção por coronavírus com interferon lambda
SE9904289D0 (sv) Method and camposition for the treatment of adenovairal ocular infections
DK0687181T3 (da) Metode til behandling af hepatitis C hos individer, som ikke responderer på interferon-behandling
BR112022006913A2 (pt) Métodos para tratar infecções virais de hepatite delta
BR0009644A (pt) Tratamento de carcinoma de célula renal
EA200800729A1 (ru) Лечение неврита зрительного нерва
EA202190594A1 (ru) Лечение вирусной инфекции гепатита дельта интерфероном лямбда
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
ATE466587T1 (de) Valeriana officinalis extrakt zur behandlung von schlafapnoe oder hypopnoe
BR112022023637A2 (pt) Composição, e, método para prevenir ou tratar uma infecção viral